西安交通大学学报（医学版）2024，Vol.45Issue(1)：55-61,7.DOI:10.7652/jdyxb202401010
BRAF突变型甲状腺癌靶向治疗耐药的研究进展
Advances in research on resistance to targeted therapy in BRAF-mutant thyroid cancer
摘要
Abstract
As the most common endocrine malignant tumor,the incidence rate of thyroid cancer is increasing year by year.However,the vast majority of subtypes have a good prognosis after traditional surgery,TSH suppression therapy and 131I treatment.With the progressive development of modern medicine,for a few thyroid cancers with poor effects of traditional treatment,molecular diagnosis and targeted therapy have further enriched the therapeutic means of thyroid cancer,in which BRAF mutation is widely present in thyroid cancer,but it often shows primary resistance or poor response to 131I therapy.The factors leading to primary or secondary resistance to targeted drugs with BRAF mutation may include genomic instability,expansion of resistant clones,occurrence of intrinsic mutations,or novel genetic and epigenetic alterations.In this article,we will review the research progress in targeted therapy resistance in BRAF-mutant thyroid cancer.关键词
BRAF基因突变/甲状腺癌/靶向治疗/耐药Key words
BRAF mutation/thyroid cancer/targeted therapy/drug resistance分类
医药卫生引用本文复制引用
耿霖,胡琳斐,阮先辉,郑向前..BRAF突变型甲状腺癌靶向治疗耐药的研究进展[J].西安交通大学学报（医学版）,2024,45(1):55-61,7.基金项目
国家自然科学基金资助项目(No.82372753,No.82172821,No.82103386,No.82272721,No.82303871),天津市医学重点学科(专科)建设项目(No.TJYXZDXK-009A)资助 Supported by the National Natural Science Foundation of China(No.82372753,No.82172821,No.82103386,No.82272721,No.82303871)and Tianjin Medical Key Discipline(Specialized)Construction Project(No.TJYXZDXK-009A) （No.82372753,No.82172821,No.82103386,No.82272721,No.82303871）
